300573.SZ
Shenyang Xingqi Pharmaceutical Co.,Ltd [300573.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
300573.SZ Stock Summary
Top 10 Correlated ETFs
300573.SZ
Top 10 Correlated Stocks
300573.SZ
In the News
300573.SZ Financial details
Company Rating
Strong Buy
Market Cap
27.91B
Income
191.18M
Revenue
1.35B
Book val./share
12.86
Cash/share
3.43
Dividend
2
Dividend %
1.19%
Employees
1.76K
Optionable
No
Shortable
Yes
Earnings
23 Oct 2023
P/E
76.98
Forward P/E
-
PEG
-315.1
P/S
14.89
P/B
9.23
P/C
62.97
P/FCF
-402.99
Quick Ratio
2.9
Current Ratio
3.4
Debt / Equity
0.04
LT Debt / Equity
0
-
-
EPS (TTM)
1.54
EPS next Y
-
EPS next Q
-
EPS this Y
8.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
58.68%
Revenue last 5Y
23.72%
Revenue Q/Q
5.13%
EPS Q/Q
38.18%
-
-
-
-
SMA20
12.18%
SMA50
45.39%
SMA100
45.39%
Inst Own
-
Inst Trans
-
ROA
10%
ROE
12%
ROC
0.13%
Gross Margin
77%
Oper. Margin
16%
Profit Margin
14%
Payout
93%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
95.0-239.5
52W High
-9.62%
52W Low
+127.37%
RSI
57
Rel Volume
1.34
Avg Volume
3.17M
Volume
4.27M
Perf Week
-2.61%
Perf Month
33.21%
Perf Quarter
41.22%
Perf Half Y
35.08%
-
-
-
-
Beta
0.031
-
-
Volatility
4.02%, 18.92%
Prev Close
-4.64%
Price
216
Change
-3.83%
300573.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.37 | 4.84 | 6.09 | 8.33 | 10.08 | |
| Net income per share | 0.17 | 0.32 | 0.78 | 1.58 | 1.71 | |
| Operating cash flow per share | 0.55 | 0.66 | 1.08 | 2.49 | 2.31 | |
| Free cash flow per share | -0.02 | 0.04 | 0.12 | 1.72 | -0.1 | |
| Cash per share | 0.16 | 0.3 | 0.33 | 5.57 | 4.16 | |
| Book value per share | 6.79 | 5.08 | 6.04 | 10.9 | 12.52 | |
| Tangible book value per share | 6.61 | 4.91 | 5.74 | 10.3 | 11.53 | |
| Share holders equity per share | 6.79 | 5.08 | 6.04 | 10.9 | 12.52 | |
| Interest debt per share | 0.66 | 0.84 | 1.03 | 0.95 | 0.12 | |
| Market cap | 1.33B | 5.87B | 7.69B | 12.05B | 11.08B | |
| Enterprise value | 1.35B | 5.91B | 7.73B | 11.48B | 10.57B | |
| P/E ratio | 97.03 | 163.5 | 87.37 | 61.89 | 52.32 | |
| Price to sales ratio | 3.07 | 10.82 | 11.16 | 11.72 | 8.86 | |
| POCF ratio | 30.11 | 79.22 | 62.92 | 39.26 | 38.69 | |
| PFCF ratio | -1.04K | 1.43K | 548.76 | 56.87 | -854.42 | |
| P/B Ratio | 2.43 | 10.32 | 11.27 | 8.96 | 7.14 | |
| PTB ratio | 2.43 | 10.32 | 11.27 | 8.96 | 7.14 | |
| EV to sales | 3.12 | 10.89 | 11.22 | 11.16 | 8.46 | |
| Enterprise value over EBITDA | 25.56 | 69.04 | 48.92 | 36.38 | 33.67 | |
| EV to operating cash flow | 30.61 | 79.76 | 63.27 | 37.39 | 36.94 | |
| EV to free cash flow | -1.05K | 1.44K | 551.81 | 54.16 | -815.72 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Free cash flow yield | 0 | 0 | 0 | 0.02 | 0 | |
| Debt to equity | 0.09 | 0.16 | 0.16 | 0.08 | 0.01 | |
| Debt to assets | 0.07 | 0.11 | 0.11 | 0.07 | 0.01 | |
| Net debt to EBITDA | 0.41 | 0.47 | 0.27 | -1.82 | -1.6 | |
| Current ratio | 1.69 | 1.27 | 1.38 | 3.69 | 5.68 | |
| Interest coverage | 3.75 | 8.46 | 17.81 | 41.46 | 266.79 | |
| Income quality | 4.89 | 2.51 | 1.31 | 1.47 | 1.35 | |
| Dividend Yield | 0.02 | 0 | 0 | 0 | 0.01 | |
| Payout ratio | 1.67 | 0.68 | 0.18 | 0.24 | 0.38 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.1 | 0.1 | 0.09 | 0.09 | 0.12 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.05 | 0.04 | 0.07 | |
| Capex to operating cash flow | -1.03 | -0.94 | -0.89 | -0.31 | -1.05 | |
| Capex to revenue | -0.11 | -0.13 | -0.16 | -0.09 | -0.24 | |
| Capex to depreciation | -1.26 | -1.73 | -2.38 | -1.41 | -4.02 | |
| Stock based compensation to revenue | 0 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Graham number | 5.1 | 6.05 | 10.28 | 19.68 | 21.93 | |
| ROIC | 0.02 | 0.05 | 0.12 | 0.15 | 0.14 | |
| Return on tangible assets | 0.02 | 0.04 | 0.1 | 0.12 | 0.13 | |
| Graham Net | -0.28 | -0.84 | -0.59 | 4.38 | 4.11 | |
| Working capital | 85.67M | 60.71M | 81.72M | 717.59M | 712.72M | |
| Tangible asset value | 531.09M | 549.82M | 648.63M | 1.27B | 1.43B | |
| Net current asset value | 55.87M | 4.31M | 22.57M | 642.07M | 634.53M | |
| Invested capital | 0.09 | 0.16 | 0.16 | 0.08 | 0.01 | |
| Average receivables | 119.23M | 133.64M | 162.19M | 189.04M | 208.82M | |
| Average payables | 8.74M | 18.55M | 16.59M | 9.99M | 16.38M | |
| Average inventory | 55.57M | 68.09M | 74.09M | 80.32M | 107.3M | |
| Days sales outstanding | 102.77 | 98.16 | 94.6 | 70.87 | 63.68 | |
| Days payables outstanding | 32.33 | 66.73 | 13.15 | 21.57 | 26.73 | |
| Days of inventory on hand | 172.21 | 200.98 | 134.75 | 149.62 | 167.98 | |
| Receivables turnover | 3.55 | 3.72 | 3.86 | 5.15 | 5.73 | |
| Payables turnover | 11.29 | 5.47 | 27.76 | 16.92 | 13.66 | |
| Inventory turnover | 2.12 | 1.82 | 2.71 | 2.44 | 2.17 | |
| ROE | 0.03 | 0.06 | 0.13 | 0.14 | 0.14 | |
| Capex per share | -0.56 | -0.62 | -0.96 | -0.77 | -2.41 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.57 | 1.98 | 2.31 | 3.22 | 3.38 | |
| Net income per share | 0.93 | 0.07 | 0.16 | 0.55 | 0.76 | |
| Operating cash flow per share | 0.93 | 0.07 | 0.16 | 0.37 | 0.98 | |
| Free cash flow per share | 0.62 | -0.39 | -0.63 | -0.01 | 0.63 | |
| Cash per share | 5.84 | 4.16 | 3.92 | 3.49 | 3.43 | |
| Book value per share | 17 | 12.52 | 12.74 | 12.74 | 12.86 | |
| Tangible book value per share | 15.66 | 11.53 | 11.32 | 11.26 | 11.36 | |
| Share holders equity per share | 17 | 12.52 | 12.74 | 12.74 | 12.86 | |
| Interest debt per share | 0.21 | 0.11 | 0.11 | 0.5 | 0.5 | |
| Market cap | 5.73B | 11.08B | 11.65B | 18.93B | 18.54B | |
| Enterprise value | 5.23B | 10.57B | 11.18B | 18.56B | 18.18B | |
| P/E ratio | 17.42 | 313.01 | 150.49 | 69.19 | 49.01 | |
| Price to sales ratio | 14.19 | 45.1 | 40.65 | 47.46 | 44.21 | |
| POCF ratio | 69.7 | 1.25K | 601.97 | 415.68 | 151.9 | |
| PFCF ratio | 104.96 | -229.47 | -148.4 | -23.5K | 238.7 | |
| P/B Ratio | 3.82 | 7.14 | 7.38 | 11.99 | 11.63 | |
| PTB ratio | 3.82 | 7.14 | 7.38 | 11.99 | 11.63 | |
| EV to sales | 12.96 | 43.06 | 39 | 46.53 | 43.34 | |
| Enterprise value over EBITDA | 52.11 | -4.32K | 394.17 | 257.3 | 164.99 | |
| EV to operating cash flow | 63.65 | 1.2K | 577.55 | 407.54 | 148.92 | |
| EV to free cash flow | 95.85 | -219.08 | -142.38 | -23.04K | 234.01 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0.01 | 0 | -0.01 | 0 | 0 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | |
| Net debt to EBITDA | -4.95 | 204.7 | -16.66 | -5.14 | -3.3 | |
| Current ratio | 4.62 | 5.68 | 4.79 | 3.78 | 3.4 | |
| Interest coverage | 493.77 | -18.98 | 145.1 | 423.64 | 233.58 | |
| Income quality | 1 | 1 | 1 | 0.67 | 1.29 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.54 | 0.01 | 0.01 | 1.3 | 0.94 | |
| Sales general and administrative to revenue | 0.25 | -0.3 | 0.11 | 0 | 0.2 | |
| Research and developement to revenue | 0.1 | 0.22 | 0.1 | 0.12 | 0.1 | |
| Intangibles to total assets | 0.07 | 0.07 | 0.1 | 0.1 | 0.1 | |
| Capex to operating cash flow | -0.34 | -6.46 | -5.06 | -1.02 | -0.36 | |
| Capex to revenue | -0.07 | -0.23 | -0.34 | -0.12 | -0.11 | |
| Capex to depreciation | -1.42 | -2.94 | -4.48 | -2.12 | 1.1 | |
| Stock based compensation to revenue | -0.05 | 0.04 | 0 | 0.03 | -0.03 | |
| Graham number | 18.87 | 4.48 | 6.69 | 12.58 | 14.86 | |
| ROIC | 0.05 | 0 | 0.01 | 0.05 | 0.06 | |
| Return on tangible assets | 0.05 | 0.01 | 0.01 | 0.04 | 0.05 | |
| Graham Net | 5.68 | 4.11 | 3.7 | 3.25 | 3.11 | |
| Working capital | 699.55M | 712.72M | 661.32M | 611.03M | 597.05M | |
| Tangible asset value | 1.38B | 1.43B | 1.4B | 1.4B | 1.41B | |
| Net current asset value | 622.89M | 634.53M | 585.97M | 537.46M | 522.28M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | |
| Average receivables | 243.32M | 243.21M | 216.05M | 242.72M | 283.81M | |
| Average payables | 10.48M | 15.2M | 18.35M | 18.72M | 16.6M | |
| Average inventory | 109.88M | 115.05M | 123.18M | 122.04M | 122.18M | |
| Days sales outstanding | 59.83 | 79.91 | 67.23 | 61.23 | 63.57 | |
| Days payables outstanding | 12.56 | 26.49 | 22.53 | 19.5 | 13.66 | |
| Days of inventory on hand | 123.71 | 166.51 | 162.18 | 115.86 | 130.72 | |
| Receivables turnover | 1.5 | 1.13 | 1.34 | 1.47 | 1.42 | |
| Payables turnover | 7.16 | 3.4 | 3.99 | 4.61 | 6.59 | |
| Inventory turnover | 0.73 | 0.54 | 0.55 | 0.78 | 0.69 | |
| ROE | 0.05 | 0.01 | 0.01 | 0.04 | 0.06 | |
| Capex per share | -0.31 | -0.46 | -0.79 | -0.37 | -0.36 |
300573.SZ Frequently Asked Questions
What is Shenyang Xingqi Pharmaceutical Co.,Ltd stock symbol ?
Shenyang Xingqi Pharmaceutical Co.,Ltd is a CN stock and trading under the symbol 300573.SZ
What is Shenyang Xingqi Pharmaceutical Co.,Ltd stock quote today ?
Shenyang Xingqi Pharmaceutical Co.,Ltd stock price is $216 today.
Is Shenyang Xingqi Pharmaceutical Co.,Ltd stock public?
Yes, Shenyang Xingqi Pharmaceutical Co.,Ltd is a publicly traded company.
Company Profile
- Volume Average 3.17M
- Market Capitalization 27.91B
- Employee 1.76K
- CEO Ms. E. Gao
- Headquarters Shenyang,CN
- IPO Date 2016-12-09
-
Website
https://www.sinqi.com 
Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.
